Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSCT for SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim
NCT01182675Phase 2Terminated
- Sponsor
- University of California, San Francisco
- Start
- Aug 2010
- Primary completion
- Sep 2013
- Modality
- Monoclonal Antibodies, Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of plerixafor, filgrastim, alemtuzumab in severe combined immunodeficiency (SCID), sponsored by University of California, San Francisco. Started Aug 2010; status: terminated.
02
Drugs
plerixaforfilgrastimalemtuzumab
03
Conditions
severe combined immunodeficiency (SCID)
Beyond the preview
Go deeper on NCT01182675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01182675.